A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : AD / abuse-deterrent

[Related PubMed/MEDLINE]
Total Number of Papers: 14
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   AD  (>> Co-occurring Abbreviation)
Long Form:   abuse-deterrent
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 Particle size affects pharmacokinetics of milled oxycodone hydrochloride tablet products following nasal insufflation in nondependent, recreational opioid users. AUCs, EDR, ER, IR, PK
2020 Extended release pellets prepared by hot melt extrusion technique for abuse deterrent potential: Category-1 in-vitro evaluation. ER, HME, PEO, PSR
2019 An in vitro approach for evaluating the oral abuse deterrence of solid oral extended-release opioids with properties intended to deter abuse via chewing. ER
2019 Evaluation of Abuse-Deterrent Characteristics of Tablets Prepared via Hot-Melt Extrusion. HME, PEO
2018 Abuse-deterrent features of an extended-release morphine drug product developed using a novel injection-molding technology for oral drug delivery. ER
2018 Human abuse potential studies of abuse-deterrent opioids: lessons from oral and intranasal studies with morphine abuse-deterrent, extended-release, injection-molded tablets. ER, HAP
2018 Interpreting labels of abuse-deterrent opioid analgesics. ADOs, FDA
2018 Principles and Methods of Statistical Assessment of Abuse-Deterrent Opioids. ER, IR
2017 Clinical relevance of the pharmacokinetic characteristics of an abuse-deterrent, extended-release, injection-molded morphine tablet. ER, IM, PK
10  2017 The ALERRT instrument: a quantitative measure of the effort required to compromise prescription opioid abuse-deterrent tablets. ADER-IMT, ER, IR
11  2016 Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users. AQ, ER, morphine-ADER-IMT, TE max, VAS
12  2016 Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users. AQ, ER, HV, i.n, LV, morphine-ADER-IMT, TDA, VAS
13  2016 Poster 457 Bioequivalence and Food Effect of a Novel, Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate Compared with a Currently Available Non-AD, ER Morphine Product. ER
14  2014 Formulation optimization of hot-melt extruded abuse deterrent pellet dosage form utilizing design of experiments. HME, TR